Meribank Biotech Past Earnings Performance
Past criteria checks 0/6
Meribank Biotech's earnings have been declining at an average annual rate of -26%, while the Healthcare industry saw earnings growing at 8% annually. Revenues have been growing at an average rate of 2% per year.
Key information
-26.0%
Earnings growth rate
-21.6%
EPS growth rate
| Healthcare Industry Growth | 9.1% |
| Revenue growth rate | 2.0% |
| Return on equity | -19.3% |
| Net Margin | -53.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Meribank Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 234 | -125 | 227 | 35 |
| 30 Sep 23 | 219 | -118 | 213 | 32 |
| 30 Jun 23 | 205 | -111 | 200 | 28 |
| 31 Mar 23 | 192 | -107 | 189 | 27 |
| 31 Dec 22 | 180 | -102 | 179 | 26 |
| 30 Sep 22 | 166 | -109 | 176 | 25 |
| 30 Jun 22 | 151 | -116 | 174 | 24 |
| 31 Mar 22 | 157 | -108 | 172 | 20 |
| 31 Dec 21 | 163 | -99 | 171 | 16 |
| 30 Sep 21 | 174 | -83 | 174 | 13 |
| 30 Jun 21 | 185 | -67 | 177 | 10 |
| 31 Mar 21 | 190 | -61 | 178 | 8 |
| 31 Dec 20 | 194 | -54 | 179 | 6 |
| 30 Sep 20 | 190 | -53 | 167 | 5 |
| 30 Jun 20 | 186 | -52 | 155 | 4 |
| 31 Mar 20 | 174 | -56 | 150 | 5 |
| 31 Dec 19 | 161 | -60 | 146 | 5 |
| 30 Sep 19 | 162 | -55 | 143 | 5 |
| 30 Jun 19 | 164 | -50 | 140 | 5 |
| 31 Mar 19 | 191 | -30 | 139 | 6 |
| 31 Dec 18 | 217 | -9 | 138 | 6 |
| 30 Sep 18 | 235 | 3 | 141 | 8 |
| 30 Jun 18 | 252 | 16 | 143 | 9 |
| 31 Mar 18 | 250 | -6 | 151 | 10 |
| 31 Dec 17 | 248 | -27 | 160 | 11 |
| 30 Sep 17 | 246 | -45 | 165 | 10 |
| 30 Jun 17 | 244 | -62 | 170 | 10 |
| 31 Mar 17 | 241 | -50 | 165 | 8 |
| 31 Dec 16 | 237 | -39 | 161 | 5 |
| 31 Dec 15 | 141 | -22 | 117 | 0 |
| 31 Dec 14 | 47 | -47 | 63 | 0 |
Quality Earnings: 4724 is currently unprofitable.
Growing Profit Margin: 4724 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4724 is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.
Accelerating Growth: Unable to compare 4724's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4724 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-2.9%).
Return on Equity
High ROE: 4724 has a negative Return on Equity (-19.29%), as it is currently unprofitable.